Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
2.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
3.

RNA editing derived epitopes function as cancer antigens to elicit immune responses.

Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, Talukder A, Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P.

Nat Commun. 2018 Sep 25;9(1):3919. doi: 10.1038/s41467-018-06405-9.

4.

Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.

Fritsche J, Rakitsch B, Hoffgaard F, Römer M, Schuster H, Kowalewski DJ, Priemer M, Stos-Zweifel V, Hörzer H, Satelli A, Sonntag A, Goldfinger V, Song C, Mahr A, Ott M, Schoor O, Weinschenk T.

Proteomics. 2018 Jun;18(12):e1700284. doi: 10.1002/pmic.201700284. Epub 2018 Apr 10.

5.

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY.

Oncoimmunology. 2017 Nov 7;7(2):e1391972. doi: 10.1080/2162402X.2017.1391972. eCollection 2018.

6.

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G.

Immunol Rev. 2017 Nov;280(1):165-174. doi: 10.1111/imr.12582. Review.

PMID:
29027230
7.

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T.

Lancet Oncol. 2016 Nov;17(11):1599-1611. doi: 10.1016/S1470-2045(16)30408-9. Epub 2016 Oct 3.

PMID:
27720136
8.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH.

Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18.

9.

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L.

Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001.

PMID:
25428506
10.

Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901.

Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H.

Oncoimmunology. 2013 Jan 1;2(1):e22246.

11.

Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.

Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V.

Cell Rep. 2012 Sep 27;2(3):628-39. doi: 10.1016/j.celrep.2012.08.006. Epub 2012 Sep 6.

12.

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H.

Nat Med. 2012 Aug;18(8):1254-61. doi: 10.1038/nm.2883. Epub 2012 Jul 29.

PMID:
22842478
13.

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.

Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, Trautwein C, Vass V, Walter S, Walker PR, Weinschenk T, Singh-Jasuja H, Dietrich PY.

Brain. 2012 Apr;135(Pt 4):1042-54. doi: 10.1093/brain/aws042. Epub 2012 Mar 14.

PMID:
22418738
14.

Tumor-associated MICA is shed by ADAM proteases.

Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A.

Cancer Res. 2008 Aug 1;68(15):6368-76. doi: 10.1158/0008-5472.CAN-07-6768.

15.

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P.

Blood. 2008 Jun 15;111(12):5610-20. doi: 10.1182/blood-2007-02-075945. Epub 2008 Feb 29.

PMID:
18310500
16.

Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen.

Boss CN, Grünebach F, Brauer K, Häntschel M, Mirakaj V, Weinschenk T, Stevanovic S, Rammensee HG, Brossart P.

Clin Cancer Res. 2007 Jun 1;13(11):3347-55.

17.

siRNA binding proteins of microglial cells: PKR is an unanticipated ligand.

Zhang Z, Weinschenk T, Guo K, Schluesener HJ.

J Cell Biochem. 2006 Apr 15;97(6):1217-29.

PMID:
16315288
18.

MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue.

Krämer BF, Schoor O, Krüger T, Reichle C, Müller M, Weinschenk T, Hennenlotter J, Stenzl A, Rammensee HG, Stevanovic S.

Cancer Biol Ther. 2005 Sep;4(9):943-8. Epub 2005 Sep 8.

PMID:
16082191
19.
20.

Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways.

Appel S, Rupf A, Weck MM, Schoor O, Brümmendorf TH, Weinschenk T, Grünebach F, Brossart P.

Clin Cancer Res. 2005 Mar 1;11(5):1928-40.

21.

Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells.

Zhang Z, Weinschenk T, Schluesener HJ.

J Neuroimmunol. 2005 Mar;160(1-2):32-40. Epub 2005 Jan 22.

PMID:
15710455
22.

Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.

Krüger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J, Weinschenk T, Müller M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanović S.

Cancer Immunol Immunother. 2005 Sep;54(9):826-36. Epub 2004 Dec 31.

PMID:
15627209
23.

CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.

Dittmann J, Keller-Matschke K, Weinschenk T, Kratt T, Heck T, Becker HD, Stevanović S, Rammensee HG, Gouttefangeas C.

Cancer Immunol Immunother. 2005 Aug;54(8):750-8. Epub 2004 Dec 22.

PMID:
15614528
24.

Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry.

Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, Stevanovic S.

Eur J Immunol. 2004 Dec;34(12):3644-51. Erratum in: Eur J Immunol. 2005 Feb;35(2):666.

25.

A conserved sequence in the mouse variable T cell receptor alpha recombination signal sequence 23-bp spacer can affect recombination.

Probst J, Blumenthal SG, Tenzer S, Weinschenk T, Dittmer J, Schoor O, Six A, Rammensee HG, Pascolo S.

Eur J Immunol. 2004 Aug;34(8):2179-90.

26.

Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes.

Schag K, Schmidt SM, Müller MR, Weinschenk T, Appel S, Weck MM, Grünebach F, Stevanovic S, Rammensee HG, Brossart P.

Clin Cancer Res. 2004 Jun 1;10(11):3658-66.

27.

Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.

Schmidt SM, Schag K, Müller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grünebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P.

Cancer Res. 2004 Feb 1;64(3):1164-70.

28.

Moderate degradation does not preclude microarray analysis of small amounts of RNA.

Schoor O, Weinschenk T, Hennenlotter J, Corvin S, Stenzl A, Rammensee HG, Stevanović S.

Biotechniques. 2003 Dec;35(6):1192-6, 1198-201.

29.

The allograft inflammatory factor-1 in Creutzfeldt-Jakob disease brains.

Deininger MH, Weinschenk T, Meyermann R, Schluesener HJ.

Neuropathol Appl Neurobiol. 2003 Aug;29(4):389-99.

PMID:
12887599
30.

Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B.

J Cancer Res Clin Oncol. 2003 Jul;129(7):397-409. Epub 2003 Jun 26.

PMID:
12836015
31.

An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope.

Seifert U, Marañón C, Shmueli A, Desoutter JF, Wesoloski L, Janek K, Henklein P, Diescher S, Andrieu M, de la Salle H, Weinschenk T, Schild H, Laderach D, Galy A, Haas G, Kloetzel PM, Reiss Y, Hosmalin A.

Nat Immunol. 2003 Apr;4(4):375-9. Epub 2003 Feb 24.

PMID:
12598896
32.

Towards patient-specific tumor antigen selection for vaccination.

Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanović S.

Immunol Rev. 2002 Oct;188:164-76. Review.

PMID:
12445290
33.

Release of regulators of angiogenesis following Hypocrellin-A and -B photodynamic therapy of human brain tumor cells.

Deininger MH, Weinschenk T, Morgalla MH, Meyermann R, Schluesener HJ.

Biochem Biophys Res Commun. 2002 Nov 8;298(4):520-30. Review.

PMID:
12408983
34.

Integrated functional genomics approach for the design of patient-individual antitumor vaccines.

Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanović S, Rammensee HG.

Cancer Res. 2002 Oct 15;62(20):5818-27.

35.
36.
37.

A role for a novel luminal endoplasmic reticulum aminopeptidase in final trimming of 26 S proteasome-generated major histocompatability complex class I antigenic peptides.

Komlosh A, Momburg F, Weinschenk T, Emmerich N, Schild H, Nadav E, Shaked I, Reiss Y.

J Biol Chem. 2001 Aug 10;276(32):30050-6. Epub 2001 May 23.

38.

Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen.

Blank M, Weinschenk T, Priemer M, Schluesener H.

J Biol Chem. 2001 May 11;276(19):16464-8. Epub 2001 Feb 13.

Supplemental Content

Loading ...
Support Center